Marie Eugenie Migaud

USPTO Granted Patents = 18 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 67(Granted Patents)

Location History:

Armagh, GB (2019)
Lurgan Armagh, GB (2018 - 2022)
Lurgan, GB (2018 - 2024)

Company Filing History:

15 out of 110

The Queen's University of Belfast

Royal College of Surgeons in Ireland

patents

4. 1 out of 902

University of Iowa Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252506 - Methods of preparing nicotinamide riboside and derivatives thereof (2025-03-18),

2. 12195494 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2025-01-14),

3. 11981698 - Methods of preparing reduced nicotinamide riboside and derivatives thereof (2024-05-14),

4. 11746123 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2023-09-05),

5. 11584770 - Methods of preparing nicotinamide riboside and derivatives thereof (2023-02-21),

6. 11376308 - Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity (2022-07-05),

7. 11345720 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2022-05-31),

8. 11274117 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2022-03-15),

9. 11242364 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2022-02-08),

10. 11071747 - Use of NAD precursors for breast enhancement (2021-07-27),

11. 10934322 - B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof (2021-03-02),

12. 10815262 - Methods of preparing nicotinamide riboside and derivatives thereof (2020-10-27),

13. 10689411 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2020-06-23),

14. 10280190 - Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions (2019-05-07),

15. 10183036 - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors (2019-01-22),

Title: Marie Eugenie Migaud: A Pioneer in Nicotinoyl Riboside Research

Introduction

Marie Eugenie Migaud is a distinguished inventor based in Lurgan, GB, known for her significant contributions to the field of chemistry. With a remarkable portfolio of 17 patents, she has been at the forefront of innovative research, particularly in the development of nicotinoyl ribosides and their derivatives. Her work has opened new avenues for applications in health and pharmaceutical industries.

Latest Patents

Among her latest patents, Migaud has introduced groundbreaking methods for the efficient and scalable synthesis of nicotinoyl ribosides and reduced nicotinoyl ribosides. Her inventive methods encompass the creation of modified derivatives, phosphorylated analogs, adenylyl dinucleotide conjugates, and various novel crystalline forms of these compounds. The patents include detailed methodologies for producing nicotinamide riboside and its derivatives, as well as compounds represented by specific chemical formulas, ensuring a wide application in medicinal chemistry.

Career Highlights

Marie Eugenie Migaud has had an impactful career, contributing her expertise to renowned institutions. She has worked at The Queen's University of Belfast, where she helped advance the scientific community's understanding of riboside chemistry. Additionally, her tenure at Chromadex Inc. has allowed her to translate her research into practical applications, making significant strides in the synthesis of vital compounds.

Collaborations

Throughout her career, Migaud has collaborated with talented professionals, including Kerri Crossey and Philip Redpath. These partnerships have enriched her research capabilities and have led to advancements in her projects, showcasing the importance of teamwork in the pursuit of scientific innovation.

Conclusion

Marie Eugenie Migaud continues to be an influential figure in her field, driving forward innovations that impact various industries. Her extensive patent portfolio reflects her dedication and expertise, making her a notable inventor whose work will have lasting implications in the world of chemistry. As she continues to explore new frontiers in research, her contributions will undoubtedly inspire future generations of scientists and inventors.

This text is generated by artificial intelligence and may not be accurate.